1448 completed. 1448 Phase 2, 227 Phase 1, 105 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1448 | Completed 1448 |
| Phase 1 | 227 | Completed 227 |
| Phase 3 | 105 | Completed 105 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride New TETA 4HCl Formulation, Standard of Care - Wilson's Disease | Phase 2 | Completed | Orphalan | 10 | 2025-07-15 | 2026-04-06 |
| GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria PORT-77, Placebo - Erythropoietic Protoporphyria (EPP) | Phase 2 | Completed | Portal Therapeutics, Inc. | 28 | 2025-04-04 | 2026-07-29 |
| A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D hepalatide - Hepatitis D | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 90 | 2024-12-11 | 2026-10-29 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. AZD2389 - Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Completed | AstraZeneca | 40 | 2024-12-06 | 2026-07-06 |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) ADX-629 - Alcohol Hepatitis | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 4 | 2024-11-04 | 2026-06-03 |
| Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems Lemborexant, Placebo - Cirrhosis, Liver Cirrhosis | Phase 2 | Completed | Universitas Indonesia | 82 | 2024-10-01 | 2026-03-18 |
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) Efinopegdutide - Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 124 | 2024-07-29 | 2026-06-01 |
| A Clinical Trial of Chazhu Xiaozhi Decoction Against Non-alcoholic Fatty Liver Disease Chazhu Xiaozhi decoction, Control placebo - Hepatic Steatosis, Symptoms and Signs | Phase 2 | Completed | Shanghai Municipal Hospital of Traditional Chinese Medicine | 70 | 2024-07-17 | 2025-04-03 |
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) Efinopegdutide, Placebo - Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 85 | 2024-07-12 | 2026-09-21 |
| Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). AHB-137 (24 weeks), AHB-137 and Placebo, AHB-137 (16 weeks) - Hepatitis B, Chronic | Phase 2 | Completed | Ausper Biopharma Co., Ltd. | 86 | 2024-07-10 | 2026-09-15 |
| A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH DD01, Placebo - NAFLD, NASH | Phase 2 | Completed | Neuraly, Inc. | 67 | 2024-06-13 | 2026-05-01 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) Foscenvivint - Liver Cirrhosis | Phase 2 | Completed | Kiminori Kimura, MD | 5 | 2024-05-08 | 2026-05-01 |
| Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink β-nicotinamide Mononucleotide, Maltodextrin - Binge Drinking, Liver Injury | Phase 1 / Phase 2 | Completed | Zhejiang Chinese Medical University | 22 | 2024-05-01 | 2025-04-10 |
| ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) ALG-055009, Placebo - NASH, MASH | Phase 2 | Completed | Aligos Therapeutics | 102 | 2024-04-01 | 2025-02-17 |
| Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients Afamelanotide 16mg implant - Erythropoietic Protoporphyria | Phase 1 / Phase 2 | Completed | Clinuvel Europe Limited | 28 | 2024-03-07 | 2026-07-27 |
| A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin - Liver Cirrhosis | Phase 2 | Completed | AstraZeneca | 73 | 2024-02-15 | 2026-01-20 |
| Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. K-808 (Dose A), K-808 (Dose B), Placebo - Primary Biliary Cholangitis | Phase 2 | Completed | Kowa Research Institute, Inc. | 46 | 2024-02-07 | 2026-10-07 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab - Hepatocellular Carcinoma, Radiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-01-25 | 2026-04-17 |
| Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH GSK4532990 - Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | GlaxoSmithKline | 61 | 2024-01-22 | 2026-10-27 |
| To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) . HSK31679 80mg, HSK31679 160mg, Placebo - Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 186 | 2024-01-05 | 2026-06-23 |
Showing 20 of 1448. Sign in to see all of them.
Carcinoma, Hepatocellular (352) · Hepatitis C (267) · Non-alcoholic Fatty Liver Disease (217) · Hepatitis C, Chronic (194) · Liver Neoplasms (162) · Hepatitis B (102) · Hepatitis B, Chronic (94) · Liver Cirrhosis (75) · Fibrosis (70) · Fatty Liver (54) · Hepatitis (53) · HIV Infections (35) · Liver Cirrhosis, Biliary (33) · Neoplasms (28)
Digestive System Diseases (1434) · Infections (587) · Virus Diseases (579) · Hepatitis, Viral, Human (574) · Hepatitis (562) · Blood-Borne Infections (560) · Communicable Diseases (557) · Pathological Conditions, Signs and Symptoms (543) · Pathologic Processes (520) · RNA Virus Infections (436) · Neoplasms by Site (415) · Digestive System Neoplasms (411) · Neoplasms (392) · Flaviviridae Infections (388)
Ribavirin (202) · peginterferon alfa-2a (117) · Sorafenib (59) · Sofosbuvir (49) · entecavir (28) · Ritonavir (27) · peginterferon alfa-2b (27) · Nivolumab (26) · daclatasvir (26) · Tenofovir (25) · ledipasvir, sofosbuvir drug combination (24) · Bevacizumab (22) · pembrolizumab (21) · Oxaliplatin (19) · Simeprevir (19)
Gilead Sciences (82) · Merck Sharp & Dohme LLC (42) · GlaxoSmithKline (41) · Bristol-Myers Squibb (40) · National Cancer Institute (NCI) (29) · Hoffmann-La Roche (27) · National Institute of Allergy and Infectious Diseases (NIAID) (26) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (25) · AbbVie (14) · Vertex Pharmaceuticals Incorporated (14) · Boehringer Ingelheim (13) · Novartis Pharmaceuticals (12) · Pfizer (12) · AbbVie (prior sponsor, Abbott) (11) · ANRS, Emerging Infectious Diseases (10)
United States (725) · France (176) · Germany (170) · Canada (161) · United Kingdom (156) · China (153) · Spain (134) · South Korea (116) · Italy (106) · Puerto Rico (103) · Belgium (98) · Taiwan (96) · Australia (82) · New Zealand (75) · Hong Kong (66)
PMID 36318027, PMID 36852452, PMID 19192962, PMID 28193518, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 37011138, PMID 42002216, PMID 16908937, PMID 20657177, PMID 23393196, PMID 23547075, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 27257978, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30420614, PMID 30850240, PMID 31568620, PMID 33657443, PMID 33666272, PMID 33856599, PMID 34256305, PMID 34635855, PMID 35179437, PMID 35291351, PMID 35771259, PMID 37183883, PMID 37696614, PMID 38780109, PMID 39326675, PMID 39356039, PMID 39437804, PMID 39950613, PMID 40116750, PMID 40434633, PMID 41042426
2016 (23), 2014 (17), 2019 (17), 2009 (14), 2015 (12), 2017 (10), 2018 (8), 2023 (7), 2008 (5), N01CM62205 (4), N01CM62207 (4), P30CA008748 (4), 2004 (3), 2005 (3), N01CM62201 (3)